论文期刊

取消

高级检索

检索历史清除

首页> Oncotarget> ATM protein is deficient in over 40% of lung adenocarcinomas.

ATM protein is deficient in over 40% of lung adenocarcinomas.

导出 OA

翻译打印收藏纠错

作者： Liza C,Villaruz ^[1] ; Helen,Jones ^[2] ; Sanja,Dacic ^[3] ; Shira,Abberbock ^[1] ; Brenda F,Kurland ^[1] ; Laura P,Stabile ^[4] ; Jill M,Siegfried ^[5] ; Thomas P,Conrads ^[6] ; Neil R,Smith ^[7] ; Mark J,O'Connor ^[2] ; Andrew J,Pierce ^[2] ; Christopher J,Bakkenist ^[2]

作者单位： University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. ^[1] Astrazeneca, Cambridge, United Kingdom. ^[2] Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. ^[3] Department of Biostatistics, University of Pittsburgh School of Public Health, Pittsburgh, PA, USA. ^[4] Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. ^[5] Department of Pharmacology, University of Minnesota, Minneapolis, MN, USA. ^[6] Inova Schar Cancer Institute, Inova Center for Personalized Health, Falls Church, VA, USA. ^[7] Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. ^[8]

关键词 ATM and Rad-3-related (ATR)ataxia telangiectasia mutated (ATM)lung adenocarcinoma non-small cell lung cancer (NSCLC)

主题词腺癌(Adenocarcinoma);成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);动物(Animals);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);顺铂(Cisplatin);DNA损伤(DNA Damage);女(雌)性(Female);人类(Humans);免疫组织化学(Immunohistochemistry);肺肿瘤(Lung Neoplasms);男(雄)性(Male);小鼠(Mice);中年人(Middle Aged);肿瘤移植(Neoplasm Transplantation);磷酰化(Phosphorylation);组织阵列分析(Tissue Array Analysis);治疗结果(Treatment Outcome)

DOI 10.18632/oncotarget.9757

PMID 27259260

发布时间 2019-02-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览41

Oncotarget

Oncotarget

2016年7卷36期

57714-57725页

相似文献

中文期刊
外文期刊
学位论文
会议论文

特别提示：本网站仅提供医学学术资源服务，不销售任何药品和器械，有关药品和器械的销售信息，请查阅其他网站。

客服热线：4000-115-888 转3 (周一至周五：8:00至17:00)
|
客服邮箱：yiyao@wanfangdata.com.cn

违法和不良信息举报电话：4000-115-888，举报邮箱：problem@wanfangdata.com.cn，举报专区

官方微信

万方医学小程序

关于我们网站地图知识产权

北京万方数据股份有限公司

万方数据电子出版社

京ICP证010071号

京公网安备11010802020237号

京ICP备08100800号-1

违法和不良信息举报电话：4000-115-888，举报邮箱：problem@wanfangdata.com.cn，举报专区

new翻译充值订阅收藏移动端

官方微信

万方医学小程序

调查问卷